Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ventrus Biosciences Inc.

This article was originally published in Start Up

Executive Summary

Like other start-up companies working to develop drugs for GI disorders, Ventrus Biosciences was attracted to the sector not only by unmet clinical needs and the focused sales opportunities, but also by the potential for creating a cross-over success: a drug that launches as a prescription product but eventually leaps over the counter to become a blockbuster, á la Claritin. Ventrus has two drug candidates ready for Phase III testing: a topical gel formulation of diltiazem, a generic vasodilator, as a treatment for anal fissures, and a novel compound it hopes will become the first new product approved for hemorrhoids in 30 years.

You may also be interested in...



Ventrus Could Start Pivotal Trial For Rx Hemorrhoid Therapy Mid-Year

The novel 5HT2a receptor antagonist would be the first FDA approved therapy for acute, non-surgical hemorrhoids, though intra-anal steroids are prescribed off-label for symptomatic relief.

Ventrus Could Start Pivotal Trial For Rx Hemorrhoid Therapy Mid-Year

The novel 5HT2a receptor antagonist would be the first FDA approved therapy for acute, non-surgical hemorrhoids, though intra-anal steroids are prescribed off-label for symptomatic relief.

Ventrus Could Start Pivotal Trial For Rx Hemorrhoid Therapy Mid-Year

Ventrus Biosciences Inc. is ready to take its lead candidate iferanserin, a novel compound aimed at arresting hemorrhoid symptoms rather than soothing them, into Phase III studies after the micro-cap biotech's late-December initial public offering brought in $20 million to support the program.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC091888

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel